Denali director plans $266K stock sale
Denali Therapeutics Inc. (DNLI) director Nancy Thornberry filed a notice of proposed sale under Rule 144 for 11,439 shares of common stock, with an indicated aggregate value of $266,128.34, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Denali Therapeutics Inc. (DNLI) director Nancy Thornberry filed a notice of proposed sale under Rule 144 for 11,439 shares of common stock, with an indicated aggregate value of $266,128.34, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
The shares were acquired from the issuer upon vesting of restricted stock units during the period from January 8, 2024 through May 31, 2025.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Units financial
aggregate value financial
NASDAQ market
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing disclose for DNLI?
When was the Form 144 notice for DNLI filed?
On which market is the DNLI stock in this Rule 144 filing to be sold?
AI-generated analysis. How Rhea-AI works. Not financial advice.